Securities Registration: Employee Benefit Plan (s-8)
March 07 2018 - 4:39PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 7, 2018
Registration
No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CytomX Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
2834
|
|
27-3521219
|
(State or other jurisdiction of
incorporation or organization)
|
|
Primary Standard Industrial
Classification Code Number)
|
|
(I.R.S. Employer
Identification Number)
|
151 Oyster Point Blvd.
Suite 400
South San
Francisco, CA 94080
(650)
515-3185
(Address, including zip code, and telephone number, including area code, of Registrants principal executive offices)
CytomX Therapeutics, Inc. 2015 Equity Incentive Plan
CytomX Therapeutics, Inc. Employee Stock Purchase Plan
(Full Title of the Plan)
Sean A.
McCarthy, D.Phil.
President and Chief Executive Officer
CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
(650)
515-3185
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Mark
V. Roeder, Esq.
Latham & Watkins LLP
140 Scott Drive
Menlo
Park, California 94025
(650)
328-4600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting
company, and emerging growth company in Rule
12b-2
of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated
filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☒
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Each Class of
Securities to be Registered
|
|
Amount
to be
Registered
(1)
|
|
Proposed
Maximum
Offering Price
Per Share
(2)
|
|
Proposed
Maximum
Aggregate
Offering Price
Per
Share
|
|
Amount of
Registration Fee
|
Common Stock, par value $0.00001 per share
|
|
1,539,142
shares
(3)
|
|
$32.33
|
|
$49,760,460.86
|
|
$6,195.18
|
Common Stock, par value $0.00001 per share
|
|
384,785
shares
(4)
|
|
$32.33
|
|
$12,440,099.05
|
|
$1,548.79
|
Total:
|
|
1,923,927 shares
|
|
$32.33
|
|
$62,200,559.91
|
|
$7,743.97
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this registration statement shall also cover any additional shares of the Registrants common stock that become
issuable under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan (the 2015 Plan) and the CytomX Therapeutics, Inc. Employee Stock Purchase Plan (the ESPP) by reason of any stock dividend, stock split, recapitalization
or similar transaction effected without the Registrants receipt of consideration which would increase the number of outstanding shares of common stock.
|
(2)
|
This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future
grant is the average of the high and low prices for the registrants common stock as reported on The NASDAQ Global Select Market on March 6, 2018, which is $32.33.
|
(3)
|
Represents the additional shares of common stock available for future issuance under the 2015 Plan resulting from an annual increase as of January 1, 2018.
|
(4)
|
Represents the additional shares of common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2018.
|
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.
EXPLANATORY NOTE
This Registration Statement on Form
S-8
is being filed for the purpose of registering an additional
1,923,927
shares of the Registrants common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form
S-8
(File Nos.
333-207694,
333-209992
and
333-215795)
are effective: (i) the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan, as a result of
the operation of an automatic annual increase provision therein, which added 1,539,142
shares of common stock, and (ii) the CytomX Therapeutics, Inc. Employee Stock Purchase Plan, as a result of the operation of an automatic annual
increase provision therein, which added 384,785
shares of common stock.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION
STATEMENT ON FORM
S-8
Pursuant to Instruction E of Form
S-8,
the contents of the Registration Statements on Form
S-8
filed with the Securities and Exchange Commission on October 30, 2015 (File No. 333-207694),
March 7, 2016 (File
No. 333-209992)
and January 27, 2017 (File
No. 333-215795)
are incorporated by reference herein; except for Item 8 which is being
updated by this Registration Statement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Filed
Herewith
|
Exhibit
Number
|
|
Exhibit Description
|
|
Form
|
|
Date
|
|
Number
|
|
|
|
|
|
|
|
|
4.1
|
|
Amended and Restated Certificate of Incorporation.
|
|
8-K
|
|
10/19/2015
|
|
3.1
|
|
|
|
|
|
|
|
|
4.2
|
|
Amended and Restated Bylaws.
|
|
8-K
|
|
10/19/2015
|
|
3.2
|
|
|
|
|
|
|
|
|
4.3
|
|
Form of Common Stock Certificate.
|
|
S-1/A
|
|
9/28/2015
|
|
4.1
|
|
|
|
|
|
|
|
|
4.4
|
|
Amended and Restated Investors Rights Agreement dated as of June
12, 2015, by and among CytomX Therapeutics, Inc. and the investors named therein.
|
|
S-1/A
|
|
8/28/2015
|
|
4.2
|
|
|
|
|
|
|
|
|
4.5
|
|
Registration Rights Agreement dated as of September
29, 2017 by and between CytomX Therapeutics, Inc. and Amgen, Inc.
|
|
10-Q
|
|
11/7/207
|
|
4.4
|
|
|
|
|
|
|
|
|
5.1
|
|
Opinion of Latham & Watkins LLP.
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
23.1
|
|
Consent of Ernst & Young LLP, Independent Registered Accounting Firm.
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
23.2
|
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Accounting Firm
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
23.3
|
|
Consent of Latham & Watkins LLP (included in Exhibit 5.1).
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
24.1
|
|
Power of Attorney. Reference is made to the signature page to the Registration Statement.
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
99.1(a)#
|
|
CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.
|
|
S-1/A
|
|
10/6/2015
|
|
10.5
|
|
|
|
|
|
|
|
|
99.1(b)#
|
|
Form of Option Award Notice under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.
|
|
10-Q
|
|
11/23/2015
|
|
10.4
|
|
|
|
|
|
|
|
|
99.1(c)#
|
|
Form of Early Exercise Option Award Notice under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.
|
|
10-Q
|
|
11/23/2015
|
|
10.5
|
|
|
#
|
Indicates management contract or compensatory plan.
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form
S-8
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco,
California, on this 7
th
day of March, 2018.
|
|
|
CytomX Therapeutics, Inc.
|
|
|
By:
|
|
/s/ Sean A. McCarthy
|
|
|
Sean A. McCarthy, D.Phil.
|
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Sean A. McCarthy and
Debanjan Ray, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful
attorney-in-fact
and agent to act for
him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact
and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all
that said
attorneys-in-fact
and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons
in the capacities and on the date indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Sean A. McCarthy
Sean A. McCarthy, D.Phil
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
March 7, 2018
|
|
|
|
/s/ Debanjan Ray
Debanjan Ray
|
|
Chief Financial Officer
(Principal Financial
and Accounting Officer)
|
|
March 7, 2018
|
|
|
|
/s/ Hoyoung Huh
Hoyoung Huh, M.D. Ph.D.
|
|
Director
|
|
March 7, 2018
|
|
|
|
/s/ Charles S. Fuchs
Charles S. Fuchs, M.D., M.P.H.
|
|
Director
|
|
March 7, 2018
|
|
|
|
/s/ Frederick W. Gluck
Frederick W. Gluck
|
|
Director
|
|
March 7, 2018
|
|
|
|
/s/ Marion McCourt
Marion McCourt
|
|
Director
|
|
March 7, 2018
|
|
|
|
/s/ John A. Scarlett
John A. Scarlett, M.D.
|
|
Director
|
|
March 7, 2018
|
|
|
|
/s/ Matthew P. Young
Matthew P. Young
|
|
Director
|
|
March 7, 2018
|
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024